Shares of Ocera Therapeutics Inc. (NASDAQ:OCRX) were down 8.4% during trading on Wednesday . The stock traded as low as $2.10 and last traded at $2.18, with a volume of 349,385 shares trading hands. The stock had previously closed at $2.38.

Separately, Zacks Investment Research cut shares of Ocera Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10th.

The firm’s market capitalization is $46.32 million. The firm’s 50-day moving average is $2.55 and its 200-day moving average is $2.70.

Ocera Therapeutics (NASDAQ:OCRX) last posted its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.02. Analysts anticipate that Ocera Therapeutics Inc. will post ($1.34) earnings per share for the current fiscal year.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.